Medical Mycology

1
MEDICAL MYCOLOGY Arthur F. Di Salvo, MD Reno,
Nevada
2
(No Transcript)
3
(No Transcript)
4
Medical Mycology Outline

• HOUR SUBJECT
• Introduction, Actinomycetes
• Yeasts, Dermatophytes
• Filamentous Fungi, Dimorphic Fungi
• Dimorphic Fungi
• Opportunistic Fungi

5
OBJECTIVES

• To impart sufficient basic science of the
  medically important fungi to assist you in
  diagnosing mycotic diseases.
• To impart sufficient clinical knowledge
• to raise your index of suspicion for mycotic
  diseases.

6
INTRODUCTION
7
(No Transcript)
8
(No Transcript)
9
(No Transcript)
10
(No Transcript)
11
Fairy Ring Mushrooms
12
What is Mycology?
13
Mycology is the study of

• Beer
• Wine
• Bread
• Cheese
• Gourmet mushrooms
• Environmental toxins
• Biodegradation
• Disease

14
(No Transcript)
15
(No Transcript)
16
(No Transcript)
17
(No Transcript)
18

19
(No Transcript)
20
BIOREMEDIATION

• Oil spills
• Cyanide in mining operations
• Dioxins and pesticides
• Produce organic acids, sugars
• Other commercial products

21
(No Transcript)
22
A. Classification
23
What is a Fungus ?

• Eukaryotic a true nucleus
• Do not contain chlorophyll
• Have cell walls
• Produce filamentous structures
• Produce spores

24
Species of Fungi

• 100,000 200,000 species
• About 300 pathogenic for man

25
 
26
 
27
(No Transcript)
28
Kingdom Fungi Eukaryocytes

• Ascomycota
• Basidiomycota
• Zygomycota
• Mitosporic Fungi
• (Fungi Imperfecti)

29
SIZE COMPARISON OF PATHOGENS
Cocci 0.8 u
Bacilli 4-6 u
Spirochetes 8 - 10 u
Viruses 0.08 u
Protozoa 15 u
Nematodes 10 mm
Fungi 10 15 u

30
Actinomyces(True Bacteria)

• Tradition
• Clinical infection resembles mycoses
• Actinomyces grow on mycotic media
• Actinomyces grow slowly (24-48 h)
• Gross colonies resemble fungi
• (rough,heaped, short aerial filaments)
• Resemble mycelia microscopically, with branched
  mycelia in tissue and smears.

31
What is Medical Mycology ?
32
MYCOTIC DISEASES(Four Types)

• Hypersensitivity
• Allergy
• Mycotoxicosis
• Production of toxin
• Mycetismus (mushroom poisoning)
• Pre-formed toxin
• Infection

33
PATHOGENIC FUNGI

• NORMAL HOST
• Systemic pathogens - 25 species
• Cutaneous pathogens - 33 species
• Subcutaneous pathogens - 10 species
• IMMUNOCOMPROMISED HOST
• Opportunistic fungi - 300 species

34
PARASITIC STATE

• Increased metabolic state
• Modified metabolic pathways
• Modified cell wall structure
• Carbohydrate content
• Lipid structure
• RNA aggregates

35
PATHOGENICITY OF FUNGI

1. Thermotolerance
2. Ability to survive in tissue environment
3. Ability to withstand host defenses

36
REVIVED INTEREST IN MYCOLOGY

• Increased frequency of mycotic diseases
• Increased awareness by physicians
• Better trained laboratory personnel
• More invasive procedures used on patients
• Increased use of immunosuppressive drugs
• Increase in immunosuppressive disease
• 7. Better laboratory diagnostic tools

37
(No Transcript)
38
B. MORPHOLOGY
39
MORPHOLGY

• Yeasts
• Hyphae (filamentous fungi, mycelium)
• Septate
• Coenocytic (non-septate)
• Dimorphic
• Yeast
• Mycelium

40
(No Transcript)
41
(No Transcript)
42
(No Transcript)
43
Dimorphic Fungi

• Yeast Form
• Parasitic form
• Tissue form
• Cultured at 37 C
• Mycelial Form
• Saprophytic form
• Cultured at 25 C

44
SPORES

• SEXUAL
• ASEXUAL
• Arthrospore
• Blastospore
• Chamydospore
• Conidia
• Microconidia
• Macroconidia

45

46
(No Transcript)
47
(No Transcript)
48
By their fruits ye shall know them

• Mathew 720

49
(No Transcript)
50
(No Transcript)
51
C. EPIDEMIOLOGY
52

• MOST MYCOTIC AGENTS
• ARE SOIL SAPRPHYTES

53
ECOLOGICAL ASSOCIATION

• PATHOGEN HUMAN SOIL
• _________________________________________
• Blastomyces dermatitidis 1898 1964
• Cryptococcus neoformans 1894 1951
• Coccidioides immitis 1900 1932
• Histoplasma capsulatum 1934 1949

54
Mycotic Diseases Are NOTContagious
55
(No Transcript)
56
ESTABLISHMENT OF INFECTION WITH A MYCOTIC AGENT
DEPENDS ON

1. Inoculum size
2. Resistance of the host

57
(No Transcript)
58
THE CLINICIAN MUST DISTINGUISH BETWEEN

• COLONIZATION
• FUNGEMIA
• INFECTION

59
PORTAL OF ENTRY
MOUTH
RESPIRATORY TRACT
EYE

• SKIN
• HAIR
• NAILS
• RESPIRATORY TRACT
• GASTROINTESTINAL TRACT
• URINARY TRACT

SKIN
UROGENITAL TRACT
ANUS
60
COLONIZATION
MOUTH
RESPIRATORY TRACT
EYE
Multiplication of an organism at a given site
without harm to the host
SKIN
UROGENITAL TRACT
ANUS
61
INFECTION
MOUTH
RESPIRATORY TRACT
EYE
Invasion and multiplication of organisms in body
tissue resulting in local cellular injury.
SKIN
UROGENITAL TRACT
ANUS
62
GEOGRAPHIC DISTRIBUTION

• The present ease and frequency of world-wide
  travel make it more likely that physicians in the
  United States will be confronted with a variety
  of unfamiliar mycoses acquired in distant parts
  of the country or of the world.

63
PATIENT HISTORY

• Medical
• Travel
• Occupation
• Avocation

64
(No Transcript)
65
(No Transcript)
66
D. DIAGNOSIS
67
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA
probes
68
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA
probes
69
DIRECT MICROSCOPIC OBSERVATION

• 10 KOH
• Gentle Heat

70
(No Transcript)
71
KOH Wet Mount
72
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
73
SKIN TESTING(DERMAL HYPERSENSTIVITY)

• Use is limited to
• Determine cellular defense mechanisms
• Epidemiologic studies

74
(No Transcript)
75
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
76
FUNGI ARE POOR ANTIGENS
77
FUNGAL SEROLOGYANTIBODIES

• Latex Agglutination IgM
• Immunodiffusion IgG
• Complement Fixation IgG

78
Most serological tests for fungi measure
antibody. Newer tests to measure antigen are now
being developed

• ANTIGEN DETECTION PRESENTLY AVAILABLE
• Cryptococcosis
• Histoplasmosis

79
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
80
DIRECT FLUORESCENT ANTIBODYCAN BE APPLIED TO

• HISTOLOGIC SECTIONS
• CULTURE
• Viable organisms
• Non-viable organisms

81
(No Transcript)
82
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probe
83
INFLAMMATORY REACTION

• Normal host
• Pyogenic
• Granulomatous
• Immunodeficient host
• Necrosis

84
Polymorphic Nuclear Leukocytes
85
Giant Cell
86
GMS
87
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
88
ISOLATION MEDIA

• SABOURAUD DEXTROSE AGAR
• (pH 5.6)
• Plain
• With antibiotics
• With cycloheximide

89
INCUBATION TEMPERATURE

• 37 C - Body temperature
• 25 C - Room temperature

90
Diagnosis1. Wet Mount2. Skin
test3. Serology4. Fluorescent antibody5.
Biopsy and histopathology6. Culture7. DNA probes
91
DNA Probes

• Rapid (1 Hour)
• Species specific
• Expensive

92
E. TREATMENT
93
THERAPY

• Because they are eukaryotic, fungi are
  biochemically similar to the human host.
  Therefore it is difficult to develop
  chemotherapeutic agents that will destroy the
  invading fungus without harming the patient.

94
A BASIC TENET OF PATHOLGY IS

• A CAUSE OF IRREVERSIBLE CELL INJURY IS CELL
  MEMBRANE DAMAGE.

95
IN FUNGAL THERAPY

• We attempt to induce cell injury by causing
  the cell membrane of the fungus to become
  permeable.

96
PROBLEM

• Finding an agent that will selectively injure
  fungal cell walls without damaging the host cell.

97
ALL EUKARYOTIC CELLS CONTAIN STEROLS

• Mammalian cells cholesterol
• Fungal cells - ergosterol

98
(No Transcript)
99
PRIMARY ANTI-FUNGAL AGENTS

• Polyene derivatives
• Amphotericin B
• Nystatin
• Azoles
• Ketoconazole
• Fluconazole
• Itraconazole
• Voriconazole

100
AMPHOTERICIN BMechanism of Action

• Amphotericin B binds to sterols
• Ergosterol is a constituent of the fungal cell
  wall
• AMB has a greater avidity for ergosterol than for
  the cholesterol in the human cell wall
• Binding to the fungal cell wall alters the
  permeability and the intracellular contents leak

101
AMPHOTERICIN BDisadvantages

• Intravenous administration
• Thrombophlebitis
• Nephrotoxic
• Fever
• Chills
• Anemia
• Long term administration

102
Azoles

• There are a few rare serious side effects from
  Itraconazole and Fluconazole

103
PRIMARY ANTI-FUNGAL AGENTS

• 3. Griseofulvin
• 4. 5-fluorocytosine (5-FC)
• 5. Allylamines
• -Terbinafine (Lamasil)
• 6. Echinocandins
• - Caspofungin

104
Griseofulvin

• A slow acting drug used for skin and nail
  infections. It accumulates in the stratum
  corneum and prevent hyphal penetration through
  these layers

105
5-fluorocytosine(5-FC)

• Interferes With RNA Synthesis

106
MECHANISMS OF ACTION

• Polyenes
• Azoles
• Griseofulvin
• 5 - FC

• Ergosterol in cell membrane
• Interfere with ergosterol synthesis
• Forms a barrier to fungal growth
• Inhibits RNA synthesis

107
(No Transcript)
108
(No Transcript)
109
F. Clinical Classification of Mycoses

• Cutaneous
• Subcutaneous
• Systemic
• Opportunistic

110
Cutaneous Mycoses

• Skin, hair and nails
• Rarely invade deeper tissue
• Dermatophytes

111
Subcutaneous Mycoses

• Confined to subcutaneous tissue and rarely spread
  systemically. The causative agents are soil
  organisms introduced into the extremities by
  trauma

112
Systemic Mycoses

• Involve skin and deep viscera
• May become widely disseminated
• Predilection for specific organs

113
OPPORTUNISTIC FUNGI

• Ubiquitous saprophytes and occasional pathogens
  that invade the tissues of those patients who
  have
• Predisposing diseases
• Diabetes, cancer, leukemia, etc.
• Predisposing conditions
• Agammaglobulinemia, steroid or
  antibiotic therapy.

114
Medical Mycology Iceberg
115
THE ESSENTIAL ELEMENT OF DIAGNOSIS IS

• A HIGH INDEX OF SUSPICION !

116
End

• Introduction